- Category: HIV Treatment
- Published on Monday, 08 July 2013 00:00
- Written by Gregory Fowler
Lowering the dosage of efavirenz (Sustiva) from 600 mg to 400 mg did not compromise its effectiveness, according to data from the ENCORE1 study presented at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur.
[Rebekah Puls speaks at IAS 2013 press conference, Kuala Lumpur, July 1, 2013]
Widespread adoption of the lower dose would "lower the cost of treatment and permit better use of scarce resources in global health budgets," Rebekah Puls from the Kirby Institute in Sydneytold reporters at a press conference prior to her late-breaker presentation. "This could mean that millions more people could receive life-saving treatment for the same amount of money."
R Puls et al (ENCORE1 Study Group). A daily dose of 400mg efavirenz (EFV) is non-inferior to the standard 600mg dose: week 48 data from the ENCORE1 study, a randomised, double-blind, placebo controlled, non-inferiority trial. 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013). Kuala Lumpur, June 30-July 3, 2013. Abstract WELBB01.